Key result
Venoarterial-extracorporeal membrane oxygenation successfully rescued 6 of 9 patients with pheochromocytoma-induced refractory cardiogenic shock, enabling myocardial recovery and subsequent surgical tumor excision.
Why the study?
Does VA-ECMO improve survival and allow for myocardial recovery in patients with pheochromocytoma-induced refractory cardiogenic shock?
Case Report (n=9)
No
Does VA-ECMO improve survival and allow for myocardial recovery in patients with pheochromocytoma-induced refractory cardiogenic shock?
VA-ECMO is an effective rescue therapy for pheochromocytoma-induced refractory cardiogenic shock, allowing for myocardial recovery and safe, delayed surgical adrenalectomy.
May support VA-ECMO rescue in pheochromocytoma shock; leaves open need for prospective validation.
BACKGROUND: Pheochromocytoma, a rare catecholamine-producing tumor, might provoke stress-induced Takotsubo-like cardiomyopathy and severe cardiogenic shock. Because venoarterial-extracorporeal membrane oxygenation (VA-ECMO) rescue of pheochromocytoma-induced refractory cardiogenic shock has rarely been reported, we reviewed our ICU patients' presentations and outcomes. METHODS: All pheochromocytoma-induced refractory cardiogenic shock cases managed with VA-ECMO (January 2007-March 2015) were prospectively included and reviewed. We also performed a systematic review on this topic. RESULTS: Nine patients (7 women, 2 men; 31-51 [median, 43 (IQR 36-49) years old]) were included; none had a previously known pheochromocytoma. Six of them had medical histories suggestive of the diagnosis: palpitations and headaches for several months for four, multiple endocrine neoplasia syndrome type 1 for one and recurrent Takotsubo disease for one; at hospital admission, all were hypertensive despite cardiogenic shock. Three others had an identified surgical triggering factor. All nine patients rapidly developed refractory cardiogenic shock with very severe left ventricular (LV) impairment (LV ejection-fraction range 5-20%; LV outflow-tract velocity-time integral range 3-8 cm). Seven patients' abdominal computed tomography scans showed pheochromocytoma-suggestive adrenal gland tumors (no scan during ICU stay for 2). Despite VA-ECMO implantation, three patients died of refractory multiple organ failure. For the six others, myocardial function improved and ECMO was removed 3-7 days post-implantation; α- and β-blockers were progressively introduced. Five survivors underwent pheochromocytoma excision 3 weeks-4 months post-ICU discharge, with satisfactory outcomes. One patient, whose pheochromocytoma was diagnosed 1 year after the index event, underwent uneventful surgical adrenalectomy. Systematic review retrieved 40 cases of pheochromocytoma-induced cardiogenic shock requiring mechanical support (mostly ECMO), with a mortality rate of 7%. Pheochromocytoma was removed surgically after mechanical support weaning in 31 patients and during mechanical support in 5. Four were not operated. CONCLUSIONS: Pheochromocytoma is a rare but reversible cause of cardiogenic shock amenable to VA-ECMO rescue. Adrenal gland imaging should be obtained for all patients with unexplained cardiogenic shock. Lastly, it might be safer to perform adrenalectomy several weeks after the initial catastrophic presentation, once recovery of LV systolic function is complete.
No takes yet. Share an insight, caveat, or question.
Hékimian et al. (2016) conducted a case report in Pheochromocytoma-induced refractory cardiogenic shock (n=9). Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) was evaluated on Survival and recovery of myocardial function. Venoarterial-extracorporeal membrane oxygenation successfully rescued 6 of 9 patients with pheochromocytoma-induced refractory cardiogenic shock, enabling myocardial recovery and subsequent surgical tumor excision.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: